Peroxisome proliferator-activated receptor-a (PPARa) mediates the diverse biological effects of peroxisome proliferator (PP) chemicals, including fatty acid catabolism, hepatomegaly, hepatocyte proliferation, and hepatocarcinogenesis in rodents. However, transgenic mice expressing a constitutively active PPARa in hepatocytes (VP16PPARa) do not develop hepatocellular carcinomas in spite of hepatocyte proliferation and hepatomegaly; this suggests that activation of genes in nonparenchymal cells may have a critical role in PP-induced carcinogenesis. VP16PPARa mice exhibited massive peroxisome proliferation and hepatomegaly as well as increased mortality upon Wy-14,643 treatment. Several genes involved in cell cycle or DNA damage repair, such as Chek1, Prkdc, Mcm, and Rad51, were significantly induced to a similar extent between wild-type and VP16PPARa mice after Wy-14,643 administration. This induction was completely abolished in Ppara-null mice, suggesting a PPARa-dependent pathway. These data revealed a DNA damage response signaling network as an early event upon PP treatment and provide novel putative mechanisms for PP-induced hepatocellular carcinoma.
INTRODUCTION
Peroxisome proliferators (PPs) represent a structurally diverse group of agents that can cause peroxisome proliferation in rodents, including the fibrate hypolipidemic drugs, phthalate ester plasticizers, and herbicides (Kersten and Wahli, 2000) . Exposure of rodents to PPs leads to hepatomegaly, peroxisome proliferation, and an increase of fatty acid catabolism as a result of enhanced expression of genes involved in lipid transport and fatty acid b-oxidation (Lazarow and De Duve, 1976; Reddy and Krishnakantha, 1975) . Chronic administration of PPs results in 100% incidence of liver tumors in rodents (Reddy et al., 1980) . However, the molecular mechanism is not completely understood.
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily, and three isoforms of PPARs (a, b/d, and c) have been identified (Dreyer et al., 1992; Issemann and Green, 1990) . PPARs act as transcription factors via a classic ligand-dependent nuclear hormone receptor mechanism. Upon binding to their ligands, PPARs undergo conformational changes that allow corepressor release and coactivator recruitment, heterodimerization with retinoid X receptor, and selective binding to specific sequences termed PP response elements in the promoter of target genes. PPARa, first cloned, identified, and named based on its ability to be activated by PPs (Issemann and Green, 1990) , serves a central role in maintaining lipid homeostasis by activating genes encoding peroxisomal and mitochondrial enzymes involved in fatty acid metabolism (Berger and Moller, 2002) .
Chronic treatment with PPARa agonist induces liver tumors via a PPARa-dependent mechanism as revealed by the resistance of Ppara-null mice to liver cancer (Hays et al., 2005; Peters et al., 1997) . However, the precise molecular mechanism leading to PPARa-induced hepatocarcinogenesis has not been fully uncovered. Recently, transgenic mice expressing a constitutively active hepatocyte-specific PPARa (VP16PPARa mice) were established using the potent viral transcriptional activator VP16 fused to mouse PPARa complementary DNA (cDNA) under the control of liverenriched activator protein (LAP) promoter . In the absence of PPARa ligands, these mice exhibit multiple hepatic responses similar to wild-type mice treated with PPs, including a decrease in serum triglycerides and free fatty acids, a massive increase in peroxisome number, and marked induction of PPARa target genes encoding fatty acid b-oxidation enzymes. However, the transgenic mice at 1 year old demonstrated no gross or microscopic evidence of either preneoplastic hepatic lesions or hepatocellular neoplasia that are evident in wild-type mice treated with PP. These results indicate that PPARa activation only in hepatocytes is not
Published by Oxford University Press 2010. sufficient to induce tumorigenesis in the liver. In the current study, the effects of Wy-14,643 on hepatocyte proliferation and gene expression patterns were compared between VP16PPARa and wild-type mice.
METHODS AND MATERIALS
Animals. Mice with hepatocyte-restricted PPARa activation in the absence of ligand (VP16PPARa) were generated as described previously . Briefly, the potent viral transcriptional activator VP16 was fused to mouse PPARa cDNA to constitutively activate PPARa-responsive genes in the absence of ligand. Then, tetracycline response element was fused to VP16PPARa to generate TREVP16PPARa transgenic mice. Subsequently, TREVP16PPARa mice were bred with mice expressing the tetracyclinecontrolled transactivator under the control of LAP to obtain the double transgenic mice (referred to herein as VP16PPARa mice). The transgenic mice were genotyped by PCR of tail DNA as described previously (Gossen and Bujard, 1992; Yang et al., 2006) . Ppara-null male mice (SV129 background; Lee et al., 1995) and corresponding wild-type counterparts (6 weeks old at the beginning of treatment) were used in these experiments.
Animal treatments. Mice were housed under a standard 12-h light-dark cycle with water and chow provided ad libitum. For Wy-14,643 treatment, mice were administrated with Wy-14,643 (0.1% [wt/wt]; Bio-Serv, Frenchtown, NJ) in the diet for indicated times. Mouse handling and all experimentation were in accordance with animal study protocols approved by the Animal Care and Use Committee at National Cancer Institute.
Histological analysis. Mice were killed by overexposure to carbon dioxide and livers excised, fixed in 10% neutral-buffered formalin (Fisher Scientific), embedded in paraffin, and 4-lm sections were prepared. Sections were stained with hematoxylin and eosin and were evaluated by light microscopy.
RNA analysis. Total RNA was isolated from livers with TRIzol reagents (Invitrogen, Carlsbad, CA). Quantitative real-time PCR (qPCR) was performed using cDNA generated from 1 lg of total RNA with SuperScript II Reverse Tanscriptase Kit (Invitrogen). qPCRs were carried out by use of SYBR Green PCR Master Mix (Applied Biosystems) in an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). Values were quantified by comparative C t methods and normalized to b-actin. The sequences for the primers used to quantify messenger RNA (mRNA) are listed in Supplementary table 1. cDNA microarray analysis. Dye-coupled cDNAs were purified with a MiniElute PCR Purification Kit (QIAGEN) and hybridized to an Agilent 44 K mouse 60-mer oligo microarray (Agilent Technologies, Santa Clara, CA). The procedures were repeated for replicate experiments with independent hybridization and processing. The data were processed and analyzed by Genespring GX software (Agilent Technologies).
Data analysis. All data were presented as mean ± SD. Differences between groups were assessed by one-way ANOVA. Differences were considered statistically significant at p < 0.05.
RESULTS

Wy-14,643 Exacerbated Hepatomegaly in VP16PPARa Mice
A fourfold increase in PPARa mRNA expression was found in the livers of VP16PPARa mice (Fig. 1A) . Western blot analysis revealed one high-mobility band from wild-type mice and two bands, corresponding to the endogenous and the lowmobility transgenic VP16PPARa fusion protein (Fig. 1B) . Antibodies against VP16 could detect one band only from the transgenic group. These results are consistent with previous findings that both endogenous PPARa and transgenic VP16PPARa are detectable by northern blot analysis in the transgenic mice . Transgenic VP16PPARa mice exhibit hepatomegaly in the absence of PP exposure. To explore the responses of transgenic mice to PPs, wild-type and VP16PPARa mice were treated with Wy-14,643 for 5 days. Compared with untreated transgenic mice and Wy-14,643-treated wild-type mice, Wy-14,643 treatment resulted in a more significant weight loss in transgenic VP16PPARa mice (Fig. 1C) . Furthermore, the liver/body weight ratio was markedly increased in these mice (Fig. 1D ). Histological analysis of liver sections revealed that transgenic mice treated with Wy-14,643 had dramatic hepatocyte hypertrophy and peroxisome proliferation (Fig. 1E) . These data suggest that PPARa activation of VP16PPARa mice by Wy-14,643 exacerbates the hepatomegaly. Because hepatocyte-specific PPARa activation only leads to hepatocyte proliferation and not liver tumors, the susceptibility of VP16PPARa mice to Wy-14,643-induced hepatocellular carcinoma was investigated. Unexpectedly, 80% of transgenic mice receiving Wy-14,643 died within 1 month; no mortality was observed in wild-type mice receiving Wy-14,643 or the VP16PPARa group without Wy-14,643 (Fig. 1F) . Coincident with the decreased survival rate is the severe hepatomegaly as revealed by liver/body weight ratio (Fig. 1G ). These data indicate that PPs may induce severe liver toxicity in the VP16PPARa mice.
PPARa Target Gene Induction in Wy-14,643-Treated VP16PPARa Mice PPARa activation regulates the transcription of numerous genes involved in fatty acid transport and oxidation. The VP16PPARa transgene in hepatocytes can induce the expression of genes encoding enzymes involved in fatty acid catabolism. Upon Wy-14,643 challenge, these genes, including acyl-CoA oxidase (Acox1), cytochrome P450 family 4a14 (Cyp4a14), and Cyp4a10, were additionally induced compared with untreated VP16PPARa mice, suggesting that VP16PPARa activity is comparable to Wy-14,643-liganded native PPARa in hepatocytes (Fig. 2) .
Regulation of Genes Involved in Hepatocyte Proliferation
and Cell Cycles by Wy-14,643 in VP16PPARa Mice Both hepatocyte and nonparenchymal cell (NPC) proliferation are important components for PP-induced hepatocellular carcinoma (Hasmall et al., 2001; Yang et al., 2007) . Proliferating cellular nuclear antigen mRNA, a marker for cell proliferation, was upregulated in Wy-14,643-treated VP16PPARa livers compared with untreated transgenic mice or 5-day Wy-14,643-treated wild-type mice, respectively (Fig. 3A) , suggesting an enhanced cell proliferation in these CONSTITUTIVE PPARa IN NONPARENCHYMAL CELLS 405 mice. Interestingly, a key oncogene cMyc, which is regulated by PPARa target miRNA let-7C after Wy-14,643 exposure (Shah et al., 2007) , was increased only in wild-type or VP16PPARa mice treated with Wy-14,643 compared with untreated wild-type or VP16PPARa mice (Fig. 3B) . Because the VP16PPARa transgene is exclusively expressed in hepatocytes, these results suggest that PPs induce a subset of genes that are critical for tumorigenesis in NPC. 
Gene Expression Profiling in Wild-Type and VP16PPARa
Transgenic Mice Livers following Wy-14,643 Treatment A previous study revealed that hepatocyte-restricted PPARa activation is sufficient to induce hepatocyte proliferation but insufficient for hepatocellular carcinoma, thus indicating an involvement of NPC activation in the development of Wy-14,643-induced liver tumors . To fully address the gene expression profile induced by Wy-14,643 treatment, microarray analysis was performed in liver samples from 5-day Wy-14,643-treated or untreated wild-type and VP16PPARa mice. As listed in Table 1 (Supplementary table  2) , the most significantly upregulated genes after Wy-14,643 treatment or untreated VP16PPARa mice were classical PPARa target genes involved in fatty acid or lipid metabolism, including Cyp4a14, fatty acid-binding protein 4 (Fabp4), Cyp4a10, Fabp3, lipoprotein lipase (Lpl), Acot1, carnitine acetyltransferase (Crat), Cd36, elongation of long chain fatty acids family 7 (Elovl7), and cell death-inducing DFFA-like effector c (Cidec), consistent with data in Figure 2 .
To gain additional insights into the Wy-14,643-induced events that link endogenous PPARa activation, cell proliferation, and liver tumor development, microarray data were further analyzed to identify genes that demonstrated exclusive activation following Wy-14,643 administration in livers from wild-type and VP16PPARa mice. Several genes were identified, and a significant numbers of genes were related to cell cycle or DNA damage repair, such as checkpoint kinase 1 homologue (Chek1), protein kinase, DNA activated, catalytic polypeptide (Prkdc), RAD51, minichromosome maintenance deficient 2 mitotin (Mcm2), Mcm5, Mcm8, and Mcm7. The above gene expression data were confirmed by qPCR analysis (Table 2, Fig. 4A ).
To further elucidate whether the induction of the above genes by Wy-14,643 is PPARa dependent, Wy-14,643 was administered to Ppara-null mice or the wild-type controls for 5 days and then qPCR was performed. As shown in Figure 4B , all the above genes, including Prkdc, Chek1, Mcm2, Mcm5, and Cyclin D1, were robustly induced in wild-type mice after Wy-14,643 treatment, whereas no induction was noted in Wy-14,643-exposed Ppara-null mice. These data demonstrate that induction of the above genes is PPARa dependent and provides putative target genes that may be critical to fibrate-induced carcinogenesis.
DISCUSSION
PPs including fibrates are nongenotoxic liver carcinogens in rodents. However, the molecular links between PPs and tumorigenesis have not been fully uncovered. In the current study, a DNA damage response signaling network, especially Chek1 and its checkpoint signaling cascades, was found to be critical to PP-induced hepatocyte proliferation and hepatocarcinomas. Although fibrates have been widely used for lowering plasma triglycerides for many years, short-term exposure of rodents to these drugs initiates a pleiotropic response of hepatomegaly, peroxisome proliferation, and increased fatty acid catabolism in liver, whereas long-term administration results in hepatocellular carcinomas. The Ppara-null mouse model revealed that PPARa is required for the pleiotropic responses (Lee et al., 1995; Peters et al., 1997) . However, the mechanism by which PPARa activation increases the incidence of hepatocellular carcinomas in rodents was not clear. Previously, characterization of the VP16PPARa mice demonstrated that activation of PPARa only in hepatocytes is sufficient to decrease triglycerides and induce hepatocellular proliferation but not liver tumors . These data suggest that activation of PPARa only in hepatocytes is not sufficient to initiate liver tumorigenesis and indicate that activation of PPARa in other liver cell types is also critical to PP-induced hepatocarcinomas. The most important difference   FIG. 2 . Induction of PPARa target genes by Wy-14,643 treatment in wildtype and VP16PPARa transgenic livers. qPCR analysis for fatty acid oxidation genes in liver from 6-to 8-week-old wild-type mice after Wy-14,643 administration for 5 days. Microsomal (Cyp4a10 and Cyp4a14, cytochrome P450 4A family) and peroxisomal (Acox, acyl-CoA oxidase) fatty acid oxidation gene expression levels were normalized to b-actin and values were mean ± SD (n ¼ 4-6). **p < 0.01 compared with wild-type control.
FIG. 3.
Changes of cell proliferation-related or cell cycle-related genes in the liver from wild-type or VP16PPARa mice exposed to Wy-14,643 for 5 days. qPCR analysis for cell proliferation marker proliferating cellular nuclear antigen and cMyc. *p < 0.05 versus wild-type group or VP16PPARa. CONSTITUTIVE PPARa IN NONPARENCHYMAL CELLS 407 between VP16PPARa transgenic mice and PP-treated wildtype counterpart is the absence of endogenous PPARa activation in the transgenic mice. The current study sought to compare the responses of VP16PPARa mice to Wy-14,643 with that of wild-type mice upon Wy-14,643 treatment. Peroxisome proliferation, hepatocyte proliferation, and hepatomegaly were greatly exacerbated by short-term Wy-14,643 treatment in transgenic mice. Moreover, a 1-month Wy-14,643 administration was sufficient to induce a striking hepatomegaly in VP16PPARa mice. Most notably, there was a dramatic increase in the mortality of VP16PPARa mice, suggesting that PPs might be of high toxicity to rodent liver as the basis of hepatomegaly.
The data from the VP16PPARa mice suggest that in addition to hepatocytes, liver NPCs are critical in PP-induced tumorigenesis. By screening microarray data, genes involved in the DNA damage response network, especially in checkpoint signaling cascades, were dramatically induced both in wildtype and in VP16PPARa liver upon Wy-14,643 challenge. Chek1 is a serine/threonine kinase that plays a critical role in cell survival and checkpoint regulation as a DNA damageinduced checkpoint regulator in enforcing cell cycle arrest (Dai and Grant, 2010) . It is also responsible for the instability of Cdc25a during an unperturbed cell cycle (Liu et al., 2006) . Chek1 is involved in DNA repair by targeting repair kinases (e.g., Prkdc), which, together with Ku70-Ku80 (designed the DNA-PK complex), are important for DSB repair (Goudelock et al., 2003) . Chek1-dependent phosphorylation of Rad51 is required for DNA damage-induced homologous recombination (Sorensen et al., 2005) . Moreover, Chek1 blocks a caspase2-dependent apoptotic response (Sidi et al., 2008) . The functions of Chek1 are consistent with putative mechanisms of PPinduced tumorigenesis: increased DNA synthesis, cell proliferation, and apoptosis suppression (Klaunig et al., 2003) . In the present study, at least three Chek1-related pathways were found upregulated in a PPARa-dependent manner: Chek1-Mcm2-7-DNA replication checkpoint, Chek1-Prkdc (DNA-PK)-DSB (double-strain break) repair, and Chek1-Rad51-HRR, indicating that DNA damage repair network may be critical in the process of PP-induced liver tumors. These findings are consistent with published data, in which genes involved in DNA damage repair were induced by fenofibrate in rats (Nishimura et al., 2007) or by 643 in mice (Woods et al., 2007) .
Although Chek1 and its downstream DNA damage repair network are induced following Wy-14,643 treatment, it is still unclear how PPARa activation upon Wy-14,643 treatment initiates DNA damage repair. One possible mechanism is oxidative stress. Treatment of rodents with PPs induces expression of genes encoding enzymes involved in peroxisomal and mitochondrial fatty acid b-oxidation, which produces reactive oxygen species as a byproduct (Woods et al., 2007; Yang et al., 2007; Yeldandi et al., 2000) . Previous studies also reported that several oxidative stress-related genes were upregulated upon PP challenge, such as Txnip, Sod2, Gpx2, and Cat (Woods et al., 2007; Yang et al., 2007) . Collectively, these studies revealed the involvement of oxidative stress in the multiple effects of PPs. Taken together, the current work demonstrates a critical role for Chek1 and its DNA damage repair network in PP-induced hepatocarcinomas as revealed by comparing the responses of VP16PPARa transgenic mice and wild-type mice to Wy-14,643 challenge, thus providing new insight into understanding the tumorigenic effects of PPs.
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